DaBomb Business Summary

DaBomb Protein Biotech Corp. (6578.TWO) operates a specialized biotechnology business model focused on the manufacturing and global distribution of hydrolyzed soy protein and functional peptides for the animal nutrition sector. The company generates revenue primarily through transaction-based sales of high-efficiency fermented proteins and postbiotic antibiotic alternatives to feed mills, commercial livestock operations, and aquaculture farms. Its primary business segments include Plant Protein (DaBomb-P for Aqua and Livestock), Antibiotic Alternatives (DBT-100 series), and a growing Pet Care division featuring LACTOTIDES and Liqui-TIDE products. Additionally, the company leverages its proprietary fermentation technology to offer Contract Development and Manufacturing Organization (CDMO) services. Within the competitive landscape, DaBomb contends with global giants such as Alltech and Nutreco, as well as regional players like Great Wall Enterprise and Biomin; it distinguishes itself as a niche leader in the Asia-Pacific market by specializing in high-purity peptide production that enhances nutrient absorption and immune response without the use of traditional antibiotics. The company is led by Chairperson Liu Yu-fen and General Manager (CEO) Chen Wei-Chen, who have overseen the firm’s transition from a traditional protein supplier to a high-value biotech entity. The leadership team possesses deep expertise in lactic acid bacteria fermentation and international quality standards, having secured triple certifications from the EU (HACCP, ISO 22000, and FAMI-QS). A pivotal element of the company’s strategic governance is its partnership with the Guohuan Enterprise Group, Taiwan’s largest animal product agent, which serves as the company’s largest single shareholder and primary domestic distribution partner. The board of directors is further supported by independent experts including Huang Hua-wei and Zhang Yong-fu, ensuring a focus on R&D-driven growth and expansion into the poultry and high-margin enzyme markets as of 2026.